W. Salzer

发表

Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.

M. Loh, J. Gastier-Foster, N. Heerema, 2015, Blood.

Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia

S. Hunger, T. Corn, B. Asselin, 2014, Annals of the New York Academy of Sciences.

Intensified PEG-L-asparaginase and Antimetabolite-based Therapy for Treatment of Higher Risk Precursor-B Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group

J. Shuster, J. Kurtzberg, M. Devidas, 2007, Journal of pediatric hematology/oncology.

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

S. Hunger, M. Devidas, N. Winick, 2013, Blood.

Paul allergy : a report from the Children ' s Oncology Group asparaginase achieves therapeutic activity after pegaspargase Erwinia

S. Hunger, M. Devidas, N. Winick, 2013 .

Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407

S. Hunger, M. Devidas, N. Winick, 2012, Pediatric blood & cancer.

Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia

E. Raetz, W. Salzer, 2010, Journal of pediatric hematology/oncology.

The genomic landscape of pediatric acute lymphoblastic leukemia

Diane A. Flasch, Samuel W. Brady, Michael C. Rusch, 2022, Nature Genetics.

Erwinia asparaginase in pediatric acute lymphoblastic leukemia

Malcolm A. Smith, N. Seibel, W. Salzer, 2012, Expert opinion on biological therapy.

Analysis of Infectious Complications in Infants With Acute Lymphoblastic Leukemia Treated on the Children's Cancer Group Protocol 1953: A Report From the Children's Oncology Group

G. Reaman, Z. Dreyer, J. Hilden, 2009, Journal of pediatric hematology/oncology.

Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid.

P. Adamson, F. Balis, B. Widemann, 2000, The Journal of pharmacology and experimental therapeutics.

Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group.

M. Loh, S. Gupta, S. Hunger, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.

R. Arceci, F. Balis, B. Widemann, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group.

N. Heerema, W. Woods, H. Sather, 2006, Blood.

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

S. Steinberg, B. Korf, N. Patronas, 2014, Neuro-oncology.

Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232.

M. Loh, J. Gastier-Foster, N. Heerema, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children’s Oncology Group Study AALL0232

M. Loh, J. Gastier-Foster, Zhiguo Chen, 2021, Leukemia.

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

Guido Marcucci, Marco Marra, Zhaohui Gu, 2016, Nature Communications.

Long-term Results Of the Pediatric Oncology Group Studies For Childhood Acute Lymphoblastic Leukemia 1984-2001: A Report From The Children’s Oncology Group

S. Hunger, M. Devidas, N. Winick, 2009, Leukemia.

Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG

M. Loh, N. Heerema, B. Wood, 2018, Haematologica.

FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631

M. Loh, N. Heerema, S. Hunger, 2021, Leukemia.

Plasma Methotrexate, Red Blood Cell Methotrexate, and Red Blood Cell Folate Values and Outcome in Children With Precursor B-acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group

Xiaomin Lu, J. Shuster, M. Devidas, 2012, Journal of pediatric hematology/oncology.

Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)

F. Behm, N. Heerema, C. Felix, 2015, Pediatric blood & cancer.

A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children’s Oncology Group Study AALL08P1

M. Loh, N. Heerema, B. Wood, 2016, Journal of pediatric hematology/oncology.

Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high‐risk stratum of patients with newly diagnosed high‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131

M. Loh, N. Heerema, B. Wood, 2018, Cancer.

Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia

B. Bostrom, Y. Messinger, Anthony J. Perissinotti, 2018, Leukemia & lymphoma.

Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131

M. Loh, N. Heerema, B. Wood, 2018, Blood.

Evaluation and Treatment of Fever in the Non‐Neutropenic Child With Cancer

S. Steinberg, F. Balis, B. Widemann, 2003, Journal of pediatric hematology/oncology.

Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232.

M. Loh, J. Gastier-Foster, N. Heerema, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children’s oncology group (COG) clinical trials

M. Loh, A. Bleyer, S. Hunger, 2018, Leukemia & lymphoma.

18‐fluorodeoxyglucose‐positron emission tomography (FDG‐PET) evaluation of nodular lesions in patients with neurofibromatosis type 1 and plexiform neurofibromas (PN) or malignant peripheral nerve sheath tumors (MPNST)

M. Whatley, B. Widemann, E. Dombi, 2013, Pediatric blood & cancer.

Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials.

M. Loh, J. Gastier-Foster, Zhiguo Chen, 2023, The Lancet. Haematology.

Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.

M. Loh, J. Gastier-Foster, N. Heerema, 2017, Blood.

Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group

M. Loh, J. Gastier-Foster, N. Heerema, 2020 .

Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131.

M. Loh, N. Heerema, B. Wood, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232

M. Loh, J. Gastier-Foster, N. Heerema, 2011 .

TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232

S. Hunger, M. Devidas, N. Winick, 2011 .

Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232.

M. Loh, J. Gastier-Foster, N. Heerema, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impaired neurocognitive functioning 3 months following diagnosis of high‐risk acute lymphoblastic leukemia: A report from the Children's Oncology Group

P. Hinds, N. Winick, K. Hardy, 2023, Pediatric blood & cancer.

Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-Lymphoblastic Leukemia (HR B-ALL): Results of Children's Oncology Group (COG) Studies AALL0232/AALL1131

M. Loh, S. Hunger, M. Devidas, 2015 .

Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children’s Oncology Group (COG) report.

M. Loh, Zhiguo Chen, N. Heerema, 2020 .

Outstanding outcomes in infants with KMT2Agermline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial

M. Loh, N. Heerema, S. Hunger, 2022, Haematologica.

Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group

M. Loh, R. Pieters, S. Hunger, 2015, Pediatric blood & cancer.

Prognostic impact of minimal residual disease at the end of consolidation in NCI standard‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group

M. Loh, N. Heerema, S. Hunger, 2021, Pediatric blood & cancer.

M. Loh, Xiaomin Lu, S. Hunger, 2015 .

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

S. Hunger, M. Devidas, N. Winick, 2013, Blood.

Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia

S. Hunger, T. Corn, B. Asselin, 2014, Annals of the New York Academy of Sciences.

Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed high risk B-lymphoblastic leukemia (HR B-ALL): Children’s Oncology Group AALL1131.

S. Hunger, M. Devidas, N. Winick, 2015 .